---
title: A Comparison of Topical Nepafenac to Placebo in Corneal Epithelial Healing Times and Postoperative Pain Relief
nct_id: NCT00330798
overall_status: COMPLETED
phase: PHASE4
sponsor: Alcon Research
study_type: INTERVENTIONAL
primary_condition: Photorefractive Keratectomy
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00330798.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00330798"
ct_last_update_post_date: 2016-11-18
last_seen_at: "2026-05-12T06:37:29.685Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# A Comparison of Topical Nepafenac to Placebo in Corneal Epithelial Healing Times and Postoperative Pain Relief

**Official Title:** A Comparison of Topical Nepafenac to Placebo in Corneal Epithelial Healing Times and Postoperative Pain Relief of Patients Status Post-Photorefractive Keratectomy: A Double-Masked Randomized Prospective Study

**NCT ID:** [NCT00330798](https://clinicaltrials.gov/study/NCT00330798)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE4
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 40
- **Lead Sponsor:** Alcon Research
- **Collaborators:** Matthew Caldwell
- **Conditions:** Photorefractive Keratectomy
- **Start Date:** 2006-02
- **Completion Date:** 2006-06
- **CT.gov Last Update:** 2016-11-18

## Brief Summary

The purpose of this study is to compare healing times and subjective pain level responses of nepafenac to placebo after photo refractive keratomileusis (PRK) surgery.

## Eligibility

- **Minimum age:** 19 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* 19 years or older with healthy ocular status and pre-operative refractive anisometropia of less than 2.000 diopters between eyes undergoing bilateral PRK surgery.
* Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

* Those desiring PRK in only one eye, those in need of additional topical eye medications, those with history of drug/alcohol abuse, women breastfeeding or pregnant.
* Other protocol-defined exclusion criteria may apply.
```

## Arms

- **Nevanac** (EXPERIMENTAL) — One drop, three times daily, in the assigned eye for the first three postoperative days
- **Acular LS** (PLACEBO_COMPARATOR) — One drop, three times daily, in the assigned eye for the first three postoperative days

## Interventions

- **nepafenac 0.1%** (DRUG) — Nepafenac 0.1% randomly assigned to one eye, with ketorolac 0.4% in the fellow eye for contralateral post-surgical use.
- **ketorolac 0.4%** (OTHER) — Keterolac 0.4% randomly assigned to one eye, with nepafenac 0.1% in the fellow eye for contralateral post-surgical use.

## Primary Outcomes

- **Subjective pain** _(time frame: Day 5)_

## Secondary Outcomes

- **Rate of epithelial healing** _(time frame: Time to event)_

## Locations (1)

- Lackland Air Force Base, San Antonio, Texas, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.lackland air force base|san antonio|texas|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00330798.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00330798*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*